Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder

Abstract Background Overactive bladder (OAB) is defined as urinary urgency accompanied by frequency and nocturia, with or without urge urinary incontinence (UUI). Vibegron, a selective β3-adrenergic receptor agonist approved in the US in December 2020, demonstrated efficacy in reducing symptoms of O...

Full description

Bibliographic Details
Main Authors: Roger R. Dmochowski, Eric S. Rovner, Michael J. Kennelly, Diane K. Newman, Laleh Abedinzadeh, Daniel Snyder, Elizabeth Thomas, Cornelia Haag-Molkenteller, Matt T. Rosenberg
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Urology
Subjects:
Adherence
Adrenergic beta-3 receptor agonists
Anticholinergic
Antimuscarinic
Medication persistence
Micturition
Online Access:https://doi.org/10.1186/s12894-023-01240-7

Internet

https://doi.org/10.1186/s12894-023-01240-7

Similar Items